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Abstract. Stroke teams are advocated for the rapid
treatment of patients who have acute ischemic stroke
(AIS) with recombinant tissue plasminogen activator
(rt-PA). An alternate model uses existing ED re-
sources with specialist consultation as needed. Ob-
jectives: To evaluate the treatment of AIS with rt-PA
in this alternate ED model. Methods: A retrospective
observational review was performed of consecutive
patients with AIS treated with rt-PA at four hospitals
affiliated with an emergency medicine residency.
Emergency physicians (EPs) were directly responsi-
ble for the treatment of all patients according to pre-
defined guidelines. Records were evaluated from the
implementation of the guidelines through December
15, 1997. Results: 37 patients with AIS received rt-
PA. Mean age 6 SD was 63 6 16 years (range 22–
87), with 25 (68%) male. Patients presented 67 6 29
minutes after stroke onset. After ED arrival, they
were seen by the EP in 14 6 13 minutes, had CT in
46 6 22 minutes, and were treated in 97 6 35
minutes. Neurologist consultation occurred in the de-
partment for nine patients (24.3%), and by telephone
for 14 (37.8%). Symptomatic intracerebral hemor-
rhage (ICH) occurred in four (10.8%, 95% CI = 0.8%
to 20.8%). There were two deaths, neither associated
with ICH. Neurologic outcome at discharge compared
with presentation in survivors was normal for four
patients (11.4%), improved for 16 (45.7%), unchanged
for ten (28.6%), and worse for five (14.3%). Conclu-
sions: In this analysis, EPs, with specialty consulta-
tion as required, successfully identified patients with
AIS and delivered rt-PA with satisfactory outcomes.
Important elements of this model include early pa-
tient identification, preestablished protocols, and
rapid access to CT scanning and interpretation. Key
words: cerebral infarction; cerebral ischemia; throm-
bolytic therapy; tissue plasminogen activator; emer-
gency medicine. ACADEMIC EMERGENCY MEDI-
CINE 1999; 6:618–625
IN DECEMBER 1995, the National Institute ofNeurological Disorders and Stroke (NINDS)
rt-PA Stroke Study Group published data demon-
strating the efficacy of recombinant tissue plas-
minogen activator (rt-PA) for the treatment of
acute ischemic stroke (AIS) when given within
three hours of symptom onset.1 Hospitals partici-
pating in the NINDS study developed teams of in-
dividuals with stroke expertise to emergently eval-
uate patients for entry into the trial, administer
the drug, and arrange admission and follow-up.2
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Though labor-intensive, this approach provided
the highest level of patient care and ensured com-
pliance with strict inclusion and exclusion criteria
defined in the study protocol. While composed pri-
marily of neurologists, some of these stroke teams
included specialists in emergency medicine (EM).
With the subsequent approval by the Food and
Drug Administration (FDA) for this use of rt-PA,
proponents have advocated the widespread devel-
opment of ‘‘stroke teams,’’ similar to those used in
the study, as one mechanism to rapidly evaluate
and treat emergency patients with symptoms of
AIS. Advantages of such a strategy include a con-
centration of thrombolytic experience in acute
stroke in a small number of individuals and the
avoidance of monopolizing a single emergency phy-
sician’s (EP’s) time in treating a single patient.
Disadvantages include the lack of availability of
specialized staffing to provide around-the-clock
coverage at many hospitals, thereby potentially
limiting patient access to emergent thrombolysis.
An alternate approach, described here as the
‘‘ED model,’’ uses EPs, with specialist consultation
as needed, as the primary individuals responsible
for evaluating patients and initiating thrombolytic
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therapy when appropriate. This model uses many
features of the ‘‘stroke team’’ approach but does not
require the resources of a standing team to re-
spond to the ED. Advantages include the use of
personnel immediately available to the patient on
ED arrival and the potential for widespread imple-
mentation in locations without stroke specialists
physically present, but available via telephone for
consultation. Potential difficulties of this model in-
clude rapidly and accurately identifying patients
with AIS, minimal individual physician experience
because of the small number of patients qualifying
for rt-PA therapy, obtaining emergent cranial CT
interpretation, and EP discomfort in being called
upon to initiate therapy with a known risk of in-
tracerebral hemorrhage (ICH).
This study reports data describing the treat-
ment of AIS with rt-PA at four southern Michigan
hospitals using this alternative ED model.
METHODS
Study Design. This was a retrospective analysis
of patients with AIS treated with rt-PA at four hos-
pitals affiliated with an EM residency. Institu-
tional review board approval was obtained for this
study.
Clinical Protocol. Following FDA approval, each
of the hospitals affiliated with the University of
Michigan and St. Joseph Mercy Hospital Emer-
gency Medicine Residency Program developed
treatment guidelines for AIS based on the NINDS
study design and recommendations of the Ameri-
can Heart Association and the American Associa-
tion of Neurology.3,4 These hospital-specific guide-
lines call for rapid evaluation of ED patients
presenting with symptoms of AIS by an EP. Emer-
gent cranial CT scans were required for all pa-
tients and read by a radiology attending or resi-
dent to ensure patients had no CT exclusions for
receiving thrombolytic therapy. Each hospital’s
guidelines included checklists to evaluate inclu-
sion and exclusion criteria for treatment with rt-
PA, guidelines for pre- and posttreatment blood
pressure control, informed consent, dosing charts,
and posttreatment intensive care unit (ICU) order
sets. Educational efforts using lectures, inservices,
and written material were directed at the physi-
cian, nursing, and ancillary staffs of EM, neurol-
ogy, radiology, neurosurgery, and the ICUs depend-
ing on the resources used at a given hospital.
All EPs at participating hospitals had potential
access to their local neurologists, as determined by
each hospital’s emergency coverage (on-call) sched-
ule, for telephone or in-person consultation. Con-
current with the retrospective analysis period, a
regional stroke team was participating in ongoing
clinical trials investigating treatment of AIS be-
yond the three-hour treatment window used for rt-
PA. This team originated in 1993 from EPs and
neurologists at the University of Michigan Medical
Center and St. Joseph Mercy Hospital with a re-
search interest in acute stroke. Members of the
team were available for consultation to EPs at the
treating hospitals for patients being evaluated for
rt-PA in the zero-to-three-hour time window. Local
treatment guidelines, however, did not mandate
consultation of any type prior to initiating therapy,
and contact was at the discretion of the treating
EP. Except for members of the stroke team, EP in-
volvement in other acute stroke research was lim-
ited to identifying potential patients and notifying
the stroke team.
All EPs treating patients with rt-PA were board-
certified in EM. As faculty in an EM residency,
they had access to conferences on the acute treat-
ment of stroke as part of the didactic program of
the residency, and had an opportunity to discuss
the treatment of stroke at staff meetings during
the development of the treatment guidelines. How-
ever, no specific educational or credentialing re-
quirements were mandated.
Study Setting and Patient Population. The
EDs participating in the clinical protocol described
above are affiliated with the University of Michi-
gan and St. Joseph Mercy Hospital Emergency
Medicine Residency Program. St. Joseph Mercy
Hospital is a 567-bed community teaching hospital
and a major teaching affiliate of the University of
Michigan School of Medicine. Annual ED census is
63,000. The University of Michigan Medical Center
is an 840-bed academic teaching hospital with an
annual ED volume of 55,000. Hurley Medical Cen-
ter, located in Flint, Michigan, is a 500-bed urban
teaching hospital affiliated with the EM residency
and additional residencies in other major special-
ties. Annual ED census is 70,000. Foote Hospital
is a 300-bed community hospital in Jackson, Mich-
igan, staffed by EPs associated with the University
of Michigan but without resident coverage. Annual
ED census is 45,000.
Study Protocol. Pharmacy records were used to
identify consecutively treated patients from the
implementation of each hospital’s treatment pro-
tocol, starting in March 1996, through December
15, 1997. These were cross-referenced with medi-
cal record searches using diagnosis-related group
(DRG) codes related to ischemic stoke and throm-
bolytic use, a concurrent stroke log maintained by
the regional stroke team, hospital ICU admission
logs, and individual physician interviews to iden-
tify all ED patients treated with rt-PA for AIS.
A study physician reviewed each identified
medical record to abstract data for spreadsheet en-
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TABLE 1. Demographics of the Treated Patients
Total patients 37







Arrived by EMS* 26 (70%)
Dominant hemisphere stroke 26 (70%)
History of hypertension 19 (51%)
History of prior stroke 4 (11%)
History of prior TIA† 3 (8%)
History of atrial fibrillation 7 (19%)
History of coronary artery disease 8 (22%)
History of diabetes 5 (14%)
Current cigarette smoking 10 (27%)
Current aspirin use 11 (30%)
*EMS = emergency medical services.
†TIA = transient ischemic attack.
try. Data sources included the patient’s emergency
medical services (EMS) ambulance record, the ED
record and the hospital record. Subsequent reha-
bilitation and clinic notes were reviewed when
available.
Data collected included information on patient
demographics, medical and social history, evalua-
tion times, physical exam findings, post-rt-PA ther-
apy complications, length of stay, and outcome.
Each patient’s pretreatment cranial CT results
were reviewed for potential treatment protocol vio-
lations. All posttreatment neuroimaging studies
obtained were reviewed for hemorrhagic or other
complications.
Data on the patient’s pretreatment NIH Stroke
Severity Score (NIHSSS) were recorded. The ED
use of the NIHSSS occurred variably during the
course of the study depending on the institution
and individual physician as a result of ongoing
educational programs. When available from the
medical record, the NIHSSS was recorded in the
database as documented. If no score was doc-
umented, the physician reviewer estimated the
score retrospectively using five-point ranges (0–5,
6–10, 11–15, 15–20, $ 20) based on the neurologic
exam documented in the medical record prior to
treatment.
The presence of ICH was entered in the data-
base if any posttreatment CT scan demonstrated
intracerebral hematoma, hemorrhagic cerebral in-
farction (hemorrhagic transformation), intraven-
tricular hemorrhage (IVH), or subarachnoid hem-
orrhage (SAH). Symptomatic ICH within 36 hours
was considered related to the use of tissue plas-
minogen activator in accordance with the NINDS
trial. This is defined as the presence of any ICH in
a patient with a prior suspicion of hemorrhage or
any decline in neurologic status.5 All CT scans of
patients with symptomatic ICH were reviewed by
an independent neuroradiologist to confirm initial
CT interpretation.
Both out-of-hospital and ED time data were col-
lected. Out-of-hospital EMS times were obtained
from run sheets for patients arriving via ambu-
lance. ED time data collected included ED arrival
as documented from initial triage, initial physician
contact as documented from nursing and physician
notes, time of cranial CT obtained from the CT im-
age time stamp, and time of initiation of rt-PA bo-
lus as obtained from the nursing record.
Data Analysis. Outcome data included length of
stay and hospital disposition. In addition, physi-
cian investigators at each hospital made a quali-
tative determination of neurologic status at dis-
charge compared with presentation; patients were
classified as normal, improved, unchanged, worse,
or deceased. Data were tabulated in a spreadsheet
and descriptive statistics calculated. Confidence
intervals for ICH rates were calculated based on
the binomial distribution. Student’s-t distribution
was used to test significance of continuous varia-
bles.
RESULTS
A total of 37 patients received rt-PA over the study
period. Demographic data for these patients are
shown in Table 1. Mean age 6 SD was 63.1 6 15.8
years. Most patients were male and presented with
right-sided symptoms, localizing to the dominant
hemisphere. Stroke severity at the time of treat-
ment is shown in Figure 1.
Out-of-hospital arrival time data were available
from two hospitals, representing 24 patients
(64.9%). Fifteen of these patients (62.5%) arrived
by EMS. Average time from onset to ED arrival
was 64 minutes for patients arriving by EMS com-
pared with 84 minutes for those arriving by car (p
= 0.25). Average time from onset to EMS dispatch
was 17 minutes, with an average scene time of 17
minutes.
Complete times for ED evaluation and treat-
ment were obtained in 34 records out of 37, and
mean interval times are shown in Table 2. Two pa-
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Figure 1. NIH Stroke Scale of treated patients.
Figure 2. Distribution of treatment time intervals.
TABLE 2. Time Intervals (Min) for Evaluation and Treatment of Patients with rt-PA*









Community teaching 17 (46.0%) 66 6 26 163 6 35 16 6 16 51 6 22 97 6 34
University teaching 7 (18.9%) 85 6 43 174 6 12 6 6 6 40 6 14 89 6 43
Urban teaching 6 (16.2%) 56 6 13 183 6 22 18 6 14 56 6 27 127 6 15
Community 7 (18.9%) 63 6 28 144 6 20 14 6 11 30 6 15 81 6 32
Combined 37 (100.0%) 67 6 29 165 6 29 14 6 13 46 6 22 97 6 35
*rt-PA = recombinant tissue plasminogen activator. Onset to ED = time from symptom onset to patient presentation; Onset to
rt-PA = time from onset of symptoms to treatment with rt-PA; Door to physician = time from ED presentation to evaluation by
emergency physician; Door to CT = time from ED presentation to CT scan; Door to rt-PA = time from ED presentation to
treatment with rt-PA.
tients had CT scan obtained at an outside hospital
before transfer to a treating facility and are not
included in the CT time intervals. For one patient,
the time seen by the EP was not available. The rt-
PA bolus began an average of 97 minutes after ar-
rival in the ED (range 38–171 minutes) and 166
minutes after stroke onset (range 61–220
minutes). Figure 2 shows the number of patients
treated at various time intervals from symptom
onset.
Neurology consultation occurred in the ED for
nine patients (24.3%) and by telephone for 14
(37.8%). No neurology consultation could be iden-
tified for the remaining 14 patients (37.8%). Of the
nine in-person consultations, seven occurred at the
university teaching hospital where the neurology
service was automatically consulted according to
local treatment guidelines. Neurology residents
provided the majority of university teaching hos-
pital consultations, but the attending EP was di-
rectly responsible for drug administration.
No records exist on telephone consultation with
the regional stroke team, although polling of team
members suggests EPs contacted the team prior to
treatment in a majority of cases. No patient
treated with rt-PA for acute stroke within zero to
three hours was personally evaluated as a consult
by a stroke research team member prior to initia-
tion of therapy. Of note, the regional stroke team
was composed primarily of EPs. These physicians
did encounter acute stroke patients in the course
of their routine ED staffing. A total of six patients
(16.2%) were treated by EP members of the re-
gional stroke team during scheduled shifts in the
ED.
Seven patients (18.9%) had treatment protocol
violations identified, all relating to administration
of rt-PA beyond the 180-minute window, with vio-
lations ranging from 1 to 40 minutes. No patient
in this group experienced a hemorrhagic compli-
cation.
A total of four patients (10.8%, 95% CI = 0.8%
to 20.8%) developed symptomatic ICH within 36
hours of treatment with rt-PA. Two had parenchy-
mal hemorrhages; review of the pretreatment cra-
nial CT scans identified one with early infarct
signs (slight hypodensity and effacement of cortical
sulci), but no evidence of mass effect. Two patients
had atypical hemorrhages compared with pub-
lished studies using rt-PA; their CT scans are
shown in Figure 3 (Patients A and B).
Patient A presented with expressive aphasia
and right face and arm weakness. After treatment
these deficits partly improved. Approximately 8
hours posttreatment, the patient’s aphasia re-
turned. A repeat head CT was obtained revealing
an isolated IVH. No further imaging was per-
formed, and the patient’s aphasia and weakness
were noted improved at the time of discharge.
Patient B presented with dysarthria and right
hemiparesis. Symptoms initially improved follow-
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Figure 3. CT scans of two of the patients with symptomatic intracerebral hemorrhage. Patient A has an isolated,
small intraventricular hemorrhage. Patient B has a left-sided ischemic stroke and a small, isolated subarachnoid
hemorrhage on the right.
ing rt-PA administration, but returned to present-
ing baseline approximately 10.5 hours after treat-
ment. A repeat CT scan demonstrated a left
hemisphere ischemic stroke and an isolated right
SAH. A third CT scan the following day remained
unchanged. At discharge the patient was found to
have both improved weakness and dysarthria com-
pared with presentation.
An additional two patients (5.4%, 95% CI = 0%
to 12.7%) had asymptomatic ICH within 36 hours
of treatment identified on routine CT scans ob-
tained prior to the initiation of anticoagulation
therapy. Two patients with late ICH were identi-
fied, one each on hospital day 3 and day 5, both
occurring in patients receiving anticoagulation
therapy for cardioembolic stroke.
Two patients died prior to discharge, neither be-
lieved related to rt-PA use. The first had a severe
stroke (NIHSSS = 24) on presentation and died
from herniation due to cerebral edema on day 6.
Posttreatment CT scan had shown no evidence of
ICH. The second death occurred on hospital day 21
in a patient awaiting nursing home placement, as
a result of a presumed pulmonary embolus.
Neurologic outcome in survivors (35) at the
time of discharge compared with presentation was
determined as normal for four patients (11.4%),
improved for 16 (45.7%), unchanged for ten
(28.6%), and worse for five (14.3%). Fifteen pa-
tients (43%) were discharged to home and 15 (43%)
to a rehabilitation facility. Three patients were dis-
charged to a nursing home, one patient was trans-
ferred to another hospital, and the disposition is
unknown for one patient. Length of stay for sur-
vivors averaged 8.1 6 6.5 days. One treated pa-
tient had a final clinical diagnosis at discharge of
suspected complex migraine.
DISCUSSION
The demonstration of efficacy of rt-PA for acute is-
chemic stroke requires a radical change in the ap-
proach to stroke patients in the emergency setting.
Recently, the NINDS has published guidelines call-
ing for the evaluation and treatment of appropri-
ate patients with AIS within 60 minutes of hospital
arrival.6 A concerted effort on the part of a variety
of providers is needed if treatment is to begin
within this time interval.
Such an effort involves improved community
education on the signs and symptoms of AIS and
the appropriate early use of 911 systems to access
medical care.7 Upon patient entry into the EMS
system, ambulance personnel must recognize the
features of a stroke in progress, minimize trans-
port time, and provide early notification to the re-
ceiving hospital of a potential acute stroke patient.
On arrival to the ED, systems must be in place to
rapidly evaluate patients for thrombolytic therapy
eligibility.
Physicians making the treatment decision must
recognize and reliably diagnose stroke and be fa-
miliar with the risks and benefits of treatment in
order to adequately inform the patient and family
members. The stroke team model is a proven ap-
proach to achieving these goals and facilitating
rapid treatment of stroke patients.2,8–10
The ED model described in this study is an al-
ternative approach based on current ED systems
used to deliver thrombolytic drugs in patients with
acute myocardial infarction (AMI).11 Patients with
chest pain are evaluated by an EP who determines
patient eligibility for thrombolytic treatment and
initiates therapy. The availability of specialty con-
sultation as needed is critical in this model, al-
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though it should not slow the initial approach to
the patient. Consultation is obtained in cardiac
cases where the diagnosis is in question, an alter-
native therapy may provide greater benefits, or for
individual physician preference.
A similar stroke therapy delivery system would
allow patients with AIS access to thrombolytic
treatment in hospitals not affiliated with dedicated
stroke teams. To our knowledge, this is the first
published series of patients with AIS treated with
rt-PA using an ED model and the data suggest a
promising initial effort in a variety of ED practice
settings.
Time intervals reported in this series compare
favorably with those reported by Chiu et al., in a
series of 30 patients treated in Houston, TX, using
a stroke team model in operation since 1992.12
Most of those patients (93%) were treated by a
member of the stroke team, which included four
neurology faculty members, three neurology fel-
lows, and a nurse coordinator. Their patients pre-
sented to the ED, on average, 10 minutes earlier
than those in the present study (57 minutes vs 67
minutes). This difference may reflect shorter trans-
port times in an urban setting, and the time is sim-
ilar to the 56-minute presentation time for the ur-
ban teaching hospital in this series. Time to CT
averaged 41 minutes and mean time to treatment
was 100 minutes in their series, compared with 47
and 97 minutes in this series. Chiu et al. also
found protocol violations for treatment after 180
minutes in 10.0% (3/30) compared with 18.9% in
this study.
Our experience suggests that deadlines are an
important element in the time to treatment.
Twenty-one of the 30 patients (70.0%) treated
within three hours of stroke onset in this series
received rt-PA within the last half-hour of the al-
lotted time. Tilley et al. reported the results of a
total quality management process related to the
NINDS rt-PA study in an attempt to reduce delays
in treatment.13 They demonstrated overall time
from ED presentation to treatment of 67 to 70
minutes. However, the time to treatment was 52
to 58 minutes in those patients randomized to
treatment within 90 minutes, compared with 78 to
86 minutes in patients randomized to receive rt-PA
between 90 and 180 minutes.
The 97-minute door-to-door treatment time re-
ported here is longer than the 60-minute goal rec-
ommended by the NINDS.6 This may reflect EP
uncertainty with a new therapy, well-meaning ef-
forts to check and recheck all treatment criteria
prior to initiation of a potentially hazardous drug,
system inefficiencies, and time taken to obtain con-
sultation and to address medicolegal concerns with
regard to hemorrhagic complications.
Emergency physicians appear to consult in a
majority of cases prior to initiation of rt-PA ther-
apy in AIS, with a minimum of 62% of patients
having some form of consultation documented.
This figure may extend higher due to the possibil-
ity of incomplete documentation, consultation with
the regional stroke team by phone rather than
with a neurologist, and treatment by stroke team
members working a routine shift in the ED. The
ability for neurologists and stroke specialists to of-
fer direction in the acute setting without a physical
presence is suggested by the finding that 61% of
all consults occurred via phone.
In the analysis of this model, EPs with specialty
consultation as clinically indicated, identified AIS
with similar diagnostic accuracy as reported in
other studies. The one patient with a discharge di-
agnosis other than AIS was a 40-year-old female
presenting with sudden onset of hemianopsia who
denied any history of headache in the ED. Neuro-
logic consultation was obtained by phone prior to
rt-PA treatment. The patient’s visual deficits sub-
sequently normalized and the discharge diagnosis
was listed as suspected complex migraine; no fol-
low-up MRI had been obtained to rule out AIS.
This 2.7% (95% CI = 0.0% to 7.1%) misdiagnosis
rate compares favorably against studies using a
stroke team approach. Chiu et al. found one pa-
tient in this series with a final diagnosis of sus-
pected psychogenic hemiparesis.12 In the NINDS
trial, 1% of all patients treated had a final neuro-
logic diagnosis other than stroke.14 In one retro-
spective series, comparing the admitting diagnosis
of EPs at a large urban teaching setting that had
a comprehensive stroke program with the dis-
charge diagnosis, the EPs correctly identified 346
of 351 patients with ischemic stroke or TIA (sen-
sitivity 98.6%, specificity 99.8%).15
The most feared complication associated with
thrombolytic treatment of AIS is ICH. The rate of
symptomatic ICH attributable to the use of rt-PA
in the present series (10.8%) was greater than that
reported in the NINDS trial (6.4%) or the Houston
series (6.7%).1,12 The number of patients in the se-
ries reported here is small, however, and the con-
fidence interval extends well below 6%. This num-
ber may also be high due to a conservative
approach on the part of the physician chart review-
ers to retrospectively ‘‘find’’ a symptom to associate
with a known ICH. In addition, two of the four ICH
patients had atypical hemorrhages, one, an iso-
lated SAH, and the second, an isolated IVH. In the
NINDS trial, four of 20 hemorrhages occurred out-
side the distribution of the stroke, but no case of
isolated SAH or IVH was reported.5 In the
GUSTO-1 trial of thrombolysis for AMI, 1.2% of the
244 cases of ICH were isolated IVH, though again,
no case of isolated SAH was identified.16 No devi-
ation from treatment protocols was identified in
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any patient with ICH, and the significance of these
atypical ICHs remains unclear.
Encouragingly, no fatality associated with ICH
was found at discharge in the series reported here,
whereas the fatality rates due to ICH at 90-day
follow-up in the NINDS trial and in the Houston
trial were 45% and 50%, respectively.1,12 This dif-
ference may be due to the small numbers in the
series above, and may reflect obvious differences
in follow-up durations.
Long-term outcome data were not obtained, and
no standardized outcome measures such as the
Barthel Index or the Modified Rankin Scale were
available in the medical record, limiting compari-
sons to published trials. At discharge, however,
51% (19/37) of the patients were qualitatively im-
proved or normal, 24% (9/37) were unchanged from
presentation, and 20% (7/20) had worsened or died.
LIMITATIONS AND FUTURE QUESTIONS
This study is limited by all weaknesses associated
with retrospective cohort studies. The potential for
exclusion of patients with AIS treated with rt-PA
exists, although using the search modality de-
scribed minimized this possibility. Physician re-
viewers were dependent on the availability and
quality of the data and evaluations made both in
the ED and subsequent hospital setting. Only pa-
tients actually treated with rt-PA were included in
this study. It is possible that patients with AIS el-
igible for treatment were not identified by the EP
or were identified but not treated due to delays in
evaluation or physician reluctance.
All of the participating hospitals had 24-hour
availability of radiology interpretation of CT scans,
either by a radiology attending or resident. This
level of support may not be duplicated at other hos-
pitals. Comparisons of EP interpretation of cranial
CT scans with radiologist interpretations found
nonconcordance in 38.7%, with potentially clini-
cally significant misinterpretations in 24.1%.17 EPs
demonstrated improved performance, reducing
major missed findings to 2.8% with no instance of
clinically significant patient mismanagement, fol-
lowing an abbreviated educational session in a fol-
low-up study.18 In addition, teleradiology technol-
ogy potentially makes specialist interpretation
available for any appropriately equipped hospital.
With institution of time-to-treatment goals and
a continuous quality management process, a fu-
ture study might examine whether the goal of
treatment within one hour of presentation can be
achieved using either the ED model or the stroke
team model. Notably, subgroup analysis of the
NINDS study data showed no correlation between
outcome and time to treatment.19 Further study to
identify such a relationship would be useful if
these time-to-treatment goals are to be widely dis-
seminated.
Finally, the impact of the presence of a regional
stroke team cannot be gauged. Though the team
did not directly evaluate treated patients, their
availability for phone consultation and ongoing re-
gional stroke education and research efforts may
be presumed to have raised overall EP awareness
on the emergent treatment of AIS.
CONCLUSION
Emergency physicians, in this retrospective anal-
ysis across a variety of practice settings, success-
fully identified patients with AIS eligible for IV
thrombolysis and delivered rt-PA therapy with sat-
isfactory outcomes. Important elements of this sys-
tem include early identification of AIS patients,
use of checkoff treatment protocols to determine
patient eligibility for thrombolytic therapy and
guide early management; rapid access to cranial
CT scans and their interpretation; and the avail-
ability of consultation, by phone or in person, with
experts familiar with the use of this treatment as
clinically required. Continued data collection is
warranted to evaluate time-to-treatment goals and
to monitor rates of ICH, accuracy of patient selec-
tion, and ultimate outcome.
This ED model potentially extends patient ac-
cess to emergent thrombolysis in AIS at institu-
tions that do not have access to the personnel re-
quired for implementation of a stroke team model.
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